Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascletis Says China Accepts Filing of Phase I GBM Trial for Review

publication date: May 25, 2021

Hangzhou's Ascletis Pharma reported that China has accepted for review the company's filing for a clinical trial of a brain cancer treatment. Ascletis intends to test a combination of ASC40 and bevacizumab in patients with recurrent glioblastoma (rGBM). ASC40 is an oral small molecule inhibitor of fatty acid synthase (FASN), a protein that regulates lipid metabolism and is present in many cancers. In 2019, Ascletis acquired China rights to the candidate from San Francisco's 3-V Biosciences for NASH. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital